within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A06A_DrugsForConstipation.A06AH05_Naldemedine;

model Naldemedine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.2,
    Cl = 5.963888888888888e-06,
    adminDuration = 600,
    adminMass = 0.2 / 1000000,
    adminCount = 1,
    Vd = 0.155,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.01,
    Tlag = 10.200000000000001,
    Vdp = 0.143,
    k12 = 1.4305555555555557e-05,
    k21 = 1.4305555555555557e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Naldemedine</td></tr><tr><td>ATC code:</td><td>A06AH05</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>0.2</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>155</td><td>L</td></tr>
    <tr><td>clearance:</td><td>21.47</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Naldemedine is a peripherally-acting μ-opioid receptor antagonist (PAMORA) used for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. It is an approved prescription medication, generally well-tolerated, and intended for oral administration.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult subjects following a single oral dose of 0.2 mg.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.A.A06AH05 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Naldemedine;
